Clinical Evaluation Finds Arch Therapeutics’ AC5® Advanced Wound System Effective in Healing Complex Chronic Wounds in Patients with Previously Unsuccessful Treatments and Significant Comorbidities
AC5® Advanced Wound System demonstrated notable improvement in healing after only 3 to 6 applications—with only weekly clinic visits and reapplication
Excerpt from the Press Release:
FRAMINGHAM, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) — Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical devices, today announced a study of its proprietary adaptive self-assembling barrier scaffold (aSABS) and peptide technology, AC5® Advanced Wound System, demonstrated marked clinical benefit in patients with significant comorbidities and nonhealing wounds. The results of the study were published in the January 2022 issue of the peer-reviewed WOUNDS journal. The manuscript is currently available online here and is expected to be available in physical form later this month.
Clinical insights gathered from the study concluded that the use of aSABS:
- had a marked effect on wound healing by interrupting the stalled inflammatory phase, reducing the bioburden of infected wound tissue, and stimulating the progression of the wound through the proper biological sequence of repair
- contributed to fast-paced healing (3 weeks in some cases)—with only weekly clinic visits and reapplication
- resulted in the healing of wounds that have been persistently inflamed and infected and for which other advanced wound products and surgical debridement had been unsuccessful—even in patients with considerable systemic comorbidities
- may offer clinicians an alternative to high-acuity operating rooms by facilitating debridement and management of some complex wounds in low-acuity outpatient clinic settings
- improved patients’ quality of life and the at-home burden of wound care for both patients and their caretakers
- may provide a favorable effect on patient morbidity and mortality in wound management
- may reduce burden on the health care system
Together, the new study along with data presented by multiple key opinion leaders at recent wound care conferences highlight the versatility and benefit of AC5® Advanced Wound System. “The insights may give new hope to patients suffering from chronic wounds,” explained Terry Norchi, MD, Chief Executive Officer of Arch Therapeutics. “Non-healing wounds can lead to cascading health problems, including amputation for many patients. These results may provide guidance to clinicians that can positively impact both patient outcomes and treatment costs,” said Norchi.
AC5® Advanced Wound System received marketing authorization by the US Food and Drug Administration and is now commercially available. A comparable product, AC5® Topical Hemostat, received a CE mark in Europe.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?